Loading clinical trials...
Loading clinical trials...
The objective of this study is to assess the efficacy and safety of 12 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the Respimat inhaler) compared with tiot...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Boehringer Ingelheim
NCT06712563 · Pulmonary Disease, Chronic Obstructive
NCT07518472 · Pulmonary Disease, Chronic Obstructive (COPD)
NCT06831994 · Asthma Bronchiale, Breast Neoplasms, and more
NCT06283004 · Pulmonary Disease, Chronic Obstructive
NCT05730088 · Pulmonary Disease, Chronic Obstructive
1237.26.10620 Boehringer Ingelheim Investigational Site
Jasper, Alabama
1237.26.10618 Boehringer Ingelheim Investigational Site
Stamford, Connecticut
1237.26.10619 Boehringer Ingelheim Investigational Site
Clearwater, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions